Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNG | P07510 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20659172 | 0.93 | HTT (0.50) | PARP1HTTKDM4EERCC5FEN1 | |
| SCHEMBL22572715 | 0.91 | HTT (0.49) | PARP1HTTKDM4EERCC5FEN1 | |
| SCHEMBL20659165 | 0.86 | GRIN2B (0.46) | PARP1HTTKDM4EERCC5FEN1 | |
| SCHEMBL3096979 | 0.85 | PARP1 (0.56) | PARP1HTTKDM4EERCC5FEN1 | |
| SCHEMBL7228337 | 0.84 | HCAR2 (0.47) | PARP1HTTKDM4EERCC5FEN1 | |
| SCHEMBL16951392 | 0.83 | PARP1 (0.54) | PARP1HTTKDM4EERCC5FEN1 | |
| SCHEMBL20659187 | 0.82 | ABCB1 (0.49) | PARP1HTTKDM4EERCC5FEN1 | |
| SCHEMBL23931574 | 0.81 | PARP1 (0.63) | PARP1HTTKDM4EERCC5FEN1 | |
| SCHEMBL13221047 | 0.81 | CTSL (0.54) | PARP1HTTKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL17187940 | 0.81 | PARP1 (0.63) | PARP1HTTKDM4EERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | claimed |
| US-6753322-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-06-22 | — | — | US | claimed |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-04-22 | — | — | US | claimed |
| EP-1292604-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | Pfizer Limited (GB) | 2003-03-19 | — | — | EP | claimed |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC. | 2002-05-16 | — | — | US | claimed |
| WO-2001094368-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-12-13 | — | — | WO | claimed |
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-7094769-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2006-06-08 | — | — | US | disclosed |
| US-6753322-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-06-22 | — | — | US | disclosed |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-04-22 | — | — | US | disclosed |
| EP-1292604-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | Pfizer Limited (GB) | 2003-03-19 | — | — | EP | disclosed |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001094368-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | PARP1 147/4885HTT 2556/4885KDM4E 2306/4885 |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | PARP1 133/4885HTT 2751/4885KDM4E 2211/4885 |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A1 | PARP1 136/4885HTT 3133/4885KDM4E 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.